LEXINGTON, Mass.--(BUSINESS WIRE)--Oct. 8, 2015--
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced the formation
of an Expert Oncology Panel to provide guidance on research and
development strategies for the Company’s portfolio of novel oncology
therapies.
Inaugural members of Synta’s Expert Oncology Panel include:
-
David E. Avigan, M.D. - Chief Section of Hematological Malignancies
and Bone Marrow Transplantation, Beth Israel Deaconess Medical Center
Associate Professor, Medicine, Harvard Medical School
-
Bruce Allan Chabner, M.D. - Director of Clinical Research, Cancer
Center Massachusetts General Hospital Cancer Center
-
Jeffrey A. Engelman, M.D., Ph.D. - Director, Center for Thoracic
Cancers Massachusetts General Hospital Cancer Center, Associate
Professor of Medicine Harvard Medical School
-
F. Stephen Hodi, Jr., M.D. - Director, Melanoma Center Director,
Center for Immuno-Oncology, Associate Professor of Medicine Harvard
Medical School, Dana Farber Cancer Institute
-
Martin J. Murphy, D. MedSc, Ph.D., FASCO - Chairman and Chief
Executive Officer AlphaMed Consulting, Inc.
-
Neil Lee Spector, M.D. - Associate Professor of Medicine, Sandra
Coates Associate Professor, Associate Professor of Pharmacology &
Cancer Biology, Member of the Duke Cancer Institute
“It is our pleasure to welcome a group of world-renowned physicians and
scientists to our newly formed Expert Oncology Panel,” said Chen Schor,
President and Chief Executive Officer of Synta. “We expect that this
panel will lend important perspective in translating the breadth of
emerging preclinical and clinical data with ganetespib into well
designed clinical studies aimed at providing meaningful clinical
benefits to cancer patients in selected indications. The advice of the
panel will also be important in shaping our HDC program strategy as we
move towards the clinic with the first candidate from this program,
STA-12-8666, and consider additional payloads for development. This
distinguished expert panel, together with our newly appointed Chief
Scientific Officer, Dr. Alan Rigby, is taking Synta one step further in
our mission to discover, develop and commercialize oncology medicines
that change cancer patients lives.”
Dr. Avigan is Professor, Department of Medicine, Harvard Medical School,
Chief, Hematological Malignancy and Bone Marrow Transplant section at
Beth Israel Deaconess Medical Center and a co-Clinical Leader of the
Leukemia Program at the Dana Farber Harvard Cancer Center. He leads a
translational research program for hematological malignancies with a
focus on vaccine therapy, tumor immunology, and stem cell biology with a
strong track record for clinical translation of biologic based
treatments. Dr. Avigan earned his M.D. from Yale University School of
Medicine, completed his residency at Columbia Presbyterian Medical
Center in Internal Medicine, and his fellowship at Memorial
Sloan-Kettering Cancer Center in Hematology/Oncology.
Dr. Chabner is the Clinical Director, Emeritus, and Paul G. Allen
Scholar at the Massachusetts General Hospital Cancer Center. During his
career at the National Cancer Institute (NCI), he served as a Senior
Investigator in the Laboratory of Chemical Pharmacology, Chief of the
Clinical Pharmacology Branch, Director of the Clinical Oncology Program,
and Director of the Division of Cancer Treatment. At the NCI, he
maintained an active laboratory program in cancer pharmacology, and led
the development of Taxol®. His research contributed significantly to the
development of high dose chemotherapy regimens, and to standard
therapies for lymphoma. Dr. Chabner is the Editor in Chief for The
Oncologist and serves on the executive advisory boards for some of the
industry's leading innovators in drug development. In 2006, Dr. Chabner
received a presidential appointment to the National Cancer Advisory
Board at the NCI, which he chaired from 2010 to 2012. Dr. Chabner earned
his M.D. at Harvard Medical School, completed his residency at Brigham
and Women’s Hospital, and his fellowships at the NCI and Yale-New Haven
Hospital.
Dr. Engelman is the Director, Center for Thoracic Cancers at the
Massachusetts General Hospital Cancer Center and an Associate Professor
of Medicine at the Harvard Medical School. The overarching aim of
research in the Engelman laboratory at Mass General is to develop new
and more effective therapeutic strategies for the treatment of cancer,
with a particular emphasis on lung cancer. Dr. Engelman is board
certified in medical oncology and earned his M.D. and Ph.D. from the
Albert Einstein College of Medicine. He completed his residency at
Brigham and Women’s Hospital and Fellowship at the Dana Farber Cancer
Institute and Massachusetts General Hospital combined program.
Dr. Hodi is the Director of the Melanoma Center and the Center for
Immuno-Oncology at Dana-Farber/Brigham and Women's Cancer Center and
Assistant Professor of Medicine at Harvard Medical School. He received
his M.D. degree from Cornell University Medical College in 1992. Dr.
Hodi competed his postdoctoral training in Internal Medicine at the
Hospital of the University of Pennsylvania, and Medical Oncology
training at Dana-Farber Cancer Institute where he joined the faculty in
1995. His research focuses on gene therapy, the development of immune
therapies, and first into human studies for malignant melanoma. Dr. Hodi
is a member of the National Comprehensive Cancer Network, the American
Society of Clinical Oncology, the Eastern Cooperative Oncology Group
Melanoma Committee, the International Society for the Biological Therapy
of Cancer, and a founding member of the Society for Melanoma Research.
Dr. Murphy is the Founding Chairman and Chief Executive
Officer of AlphaMed Consulting, Inc., a consultancy that provides
strategic support for academic cancer centers and cancer drug
development programs of global pharmaceutical and biotechnology
companies. He is the founding Executive Editor of three journals: The
Oncologist, Stem Cells and of Stem Cells Translational Medicine. Dr.
Murphy was founding Chief Executive Officer of Hipple Cancer Research
Center and an NIH principal investigator who merited more than $25
million in competitive NIH grants. He is Co-founder of the Society for
Translational Oncology, a member of the Scientific Advisory Board
of Hatteras Venture Partners, a charter member of the International
Advisory Board of Amsterdam’s VU University Medical Imaging Center, a
charter member of Queen's University-Belfast School of Medicine
International Review Board, Chairman Emeritus of the Conquer Cancer
Foundation of the American Society of Clinical Oncology (ASCO), convener
of ACT-China, and Steering Committee Member and Senior Consultant of
the Chinese Society of Clinical Oncology. He is also a member of
the National Cancer Policy Forum of the National Academy of Medicine of
the United States National Academy of Sciences, a director of
the Foundation for the National Institutes of Health, a member of
the Board of Visitors of the UNC Lineberger Comprehensive Cancer Center,
a member of the Board of Advisors of the H. Lee Moffitt Cancer Center &
Research Institute and a charter member and vice chairman of C-Change,
founded by former President George H.W. Bush and former First Lady
Barbara Bush. Dr. Murphy is a Fellow of the American Society of Clinical
Oncology and is Founding Chief Executive Officer of the non-profit CEO
Roundtable on Cancer at the request of the Forty-First President George
H.W. Bush.
Dr. Spector is the Sandra Coates Chair Breast Cancer Research at the
Duke University Medical Center, Leader of the Developmental Therapeutics
Program, Duke Cancer Institute, and currently serves as Scientific
Advisor to Synta. Prior to joining Duke, Dr. Spector served as Director
of GlaxoSmithKline’s Exploratory Medical Sciences in Oncology, where he
successfully guided the development of Tykerb® (lapatinib) and Arranon®
(nelarabine) from initial preclinical studies through clinical
development and eventual FDA approval. Dr. Spector is board-certified in
Hematology, Medical Oncology and Internal Medicine and earned his M.D.
at the University of Medicine and Dentistry of New Jersey. He completed
his residency in Internal Medicine at Parkland Memorial Hospital,
University of Texas, Southwestern Medical Center and in Medical
Oncology/Hematology at the Dana Farber Cancer Institute and
Massachusetts General Hospital combined program.
About Synta Pharmaceuticals
Synta Pharmaceuticals Corp. is an innovative, agile biopharmaceutical
company focused on research, development and commercialization of novel
oncology medicines that have the potential to change the lives of cancer
patients. Synta’s lead oncology drug candidate, ganetespib, a novel heat
shock protein 90 (Hsp90) inhibitor, is currently being evaluated in
several clinical trials including the pivotal GALAXY-2 Phase 3 trial in
non-small cell lung cancer. Building on its extensive expertise in the
science of Hsp90, Synta also has a novel proprietary Hsp90 inhibitor
Drug Conjugate (HDC) small molecule drug development program. IND
enabling studies have commenced for the first clinical candidate from
the HDC program, STA-12-8666, and preclinical evaluation of additional
HDC candidates is ongoing. For more information, please visit www.syntapharma.com.
Safe Harbor Statement
This media release may contain forward-looking statements about Synta
Pharmaceuticals Corp. Such forward-looking statements can be identified
by the use of forward-looking terminology such as "will", "would",
"should", "expects", "anticipates", "intends", "plans", "believes",
"may", "estimates", "predicts", "projects", or similar expressions
intended to identify forward-looking statements. Such statements reflect
Synta’s current views with respect to future events and are based on
assumptions and subject to risks and uncertainties that could cause
actual results to differ materially from those expressed or implied by
such forward-looking statements, including those described in "Risk
Factors" of our Form 10-K for the year ended December 31, 2014 as filed
with the Securities and Exchange Commission. Synta undertakes no
obligation to publicly update forward-looking statements, whether
because of new information, future events or otherwise, except as
required by law.
Tykerb® and Arranon® are registered trademarks of the GlaxoSmithKline
group of companies.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151008005630/en/
Source: Synta Pharmaceuticals Corp.
Investors:
Synta Pharmaceuticals Corp.
Daniel Cole,
781-541-7250
[email protected]
or
Argot
Partners
Andrea Rabney, 212-600-1494
[email protected]
or
Media:
Argot
Partners
Eliza Schleifstein, 917-763-8106
[email protected]